Neuralink, Elon Musk’s brain-chip company, has achieved a significant milestone with the US Food and Drug Administration (FDA) granting its experimental Blindsight implant the prestigious “breakthrough device” designation.
Designed to overcome vision loss, Blindsight is a groundbreaking device that can restore vision in those with partial or complete blindness, including cases where optic nerves are non-functional.
“Neuralink is pleased to announce receipt of the FDA’s Breakthrough Device Designation for Blindsight. We invite individuals interested in restoring their vision to join our Patient Registry and explore career opportunities on our website.
According to Reuters, the FDA awards its breakthrough designation to medical devices that treat or diagnose life-threatening conditions, expediting their development and review.
Musk also announced the update on his X social media platform, highlighting Blindsight’s potential to restore vision in even the most severe blindness cases.
“The Blindsight device from Neuralink will enable even those who have lost both eyes and their optic nerve to see.
“Provided the visual cortex is intact, it will even enable those who have been blind from birth to see for the first time.
“To set expectations correctly, the vision will be at first be low resolution, like Atari graphics, but eventually it has the potential to be better than natural vision and enable you to see in infrared, ultraviolet or even radar wavelengths, like Geordi La Forge.” Musk wrote on X.com.
Neuralink, co-founded by Elon Musk in 2016, specialises in developing innovative brain-computer interfaces to transform treatments for neurological disorders.
Neuralink’s technology includes a brain implant that reads neural signals and wirelessly transmits them to external devices, including computers and mobile devices.
Business World reports that Neuralink is also developing an implant that enables paralyzed individuals to control digital devices with their thoughts.
Neuralink is also reported to be conducting a clinical trial with three participants to evaluate the device’s effectiveness in aiding individuals with spinal cord injuries.
It was widely reported in August 2024 that Neuralink’s brain-computer interface was successfully implanted in a second patient, who is now controlling video games and creating 3D designs using only their thoughts.
Leave a comment